Skip to main content

Advertisement

SpringerLink
Log in

Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rini BI and Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028–1043

    Article  CAS  Google Scholar 

  2. Escudier B et al. (2005) Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract #4510]. J Clin Oncol 23 (Suppl)

  3. Bukowski RM et al. (2006) Bevacizumab with or without erlotinib in metastatic renal cell carcinoma [abstract #4523]. J Clin Oncol 24 (Suppl)

  4. Motzer RJ et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516–2524

    Article  CAS  Google Scholar 

  5. Hudes G et al. (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) [abstract #LBA4]. J Clin Oncol 24 (Suppl)

Download references

Acknowledgements

The synopsis was written by Carol Lovegrove, Freelance Medical Writer.

Author information

Authors and Affiliations

  1. staff member in the Department of Solid Tumor Oncology at the Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

    Brian I Rini

Authors
  1. Brian I Rini
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has received research support and is an advisor to Bayer and Onyx Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rini, B. Stabilization of disease in patients with metastatic renal cell carcinoma using sorafenib. Nat Rev Clin Oncol 3, 602–603 (2006). https://doi.org/10.1038/ncponc0634

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0634

  • Springer Nature Limited

This article is cited by

Search

Navigation